Related Articles for PubMed (Select 15631627)

Human lung cancer cells express functionally active Toll-like receptor 9.

Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T.

Respir Res. 2005 Jan 4;6:1.

PMID: 15631627 [PubMed - indexed for MEDLINE]

Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis.

Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L.

Cancer Biol Ther. 2007 Nov;6(11):1704-9. Epub 2007 Aug 3.

PMID: 17986857 [PubMed - indexed for MEDLINE]

Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.

Ren T, Wen ZK, Liu ZM, Qian C, Liang YJ, Jin ML, Cai YY, Xu L.

Cancer Invest. 2008 Jun;26(5):448-55.

PMID: 18568766 [PubMed - indexed for MEDLINE]

CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo.

Knuefermann P, Baumgarten G, Koch A, Schwederski M, Velten M, Ehrentraut H, Mersmann J, Meyer R, Hoeft A, Zacharowski K, Grohé C.

Respir Res. 2007 Oct 9;8:72.

PMID: 17925007 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.

Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS.

Mol Cancer Res. 2008 Oct;6(10):1534-43.

PMID: 18922969 [PubMed - indexed for MEDLINE]

Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA.

Suzuki K, Suda T, Naito T, Ide K, Chida K, Nakamura H.

Am J Respir Crit Care Med. 2005 Apr 1;171(7):707-13. Epub 2005 Jan 7.

PMID: 15640365 [PubMed - indexed for MEDLINE]

Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.

Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS.

Prostate. 2007 May 15;67(7):774-81.

PMID: 17373717 [PubMed - indexed for MEDLINE]

Increased expression of Toll-like receptors 4 and 9 in human lung cancer.

Zhang YB, He FL, Fang M, Hua TF, Hu BD, Zhang ZH, Cao Q, Liu RY.

Mol Biol Rep. 2008 Sep 2. [Epub ahead of print]

PMID: 18763053 [PubMed - as supplied by publisher]

CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.

Roda JM, Parihar R, Carson WE 3rd.

J Immunol. 2005 Aug 1;175(3):1619-27.

PMID: 16034101 [PubMed - indexed for MEDLINE]

10:

Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM.

Immunology. 2004 Oct;113(2):212-23.

PMID: 15379982 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

11:

Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.

Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS.

Mol Cancer Res. 2006 Jul;4(7):437-47.

PMID: 16849519 [PubMed - indexed for MEDLINE]

12:

Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium.

Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J.

Clin Exp Immunol. 2005 Aug;141(2):298-306.

PMID: 15996194 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

13:

CpG DNA modulates interleukin 1beta-induced interleukin-8 expression in human bronchial epithelial (16HBE14o-) cells.

Parilla NW, Hughes VS, Lierl KM, Wong HR, Page K.

Respir Res. 2006 Jun 1;7:84.

PMID: 16740161 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

14:

[Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer]

Ren T, Cai YY, Liang YJ, Jin ML, Guo ZL, Tao MF, He X.

Zhonghua Yi Xue Za Zhi. 2008 Apr 29;88(17):1168-72. Chinese.

PMID: 18844109 [PubMed - in process]

15:

Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression.

Griebel PJ, Brownlie R, Manuja A, Nichani A, Mookherjee N, Popowych Y, Mutwiri G, Hecker R, Babiuk LA.

Vet Immunol Immunopathol. 2005 Oct 18;108(1-2):11-6. Review.

PMID: 16098606 [PubMed - indexed for MEDLINE]

16:

Decreased intracellular TLR9 confers hyporesponsiveness of RAW264.7 cells to subsequent CpG ODN challenge.

Wei L, Hong Z, Jiang Z, Guofu D, Hongwei C, Liangxi W, Yongling L, Bin L, Ping L.

Int Immunopharmacol. 2006 Jun;6(6):935-46. Epub 2006 Feb 3.

PMID: 16644479 [PubMed - indexed for MEDLINE]

17:

Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.

Merlo A, Calcaterra C, Mènard S, Balsari A.

J Leukoc Biol. 2007 Sep;82(3):509-18. Epub 2007 Jun 22.

PMID: 17586660 [PubMed - indexed for MEDLINE]

18:

Expression of TLR9 within human glioblastoma.

Meng Y, Kujas M, Marie Y, Paris S, Thillet J, Delattre JY, Carpentier AF.

J Neurooncol. 2008 May;88(1):19-25. Epub 2008 Feb 6.

PMID: 18253698 [PubMed - indexed for MEDLINE]

19:

Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-alpha.

Schroeder JT, Chichester KL, Bieneman AP.

J Allergy Clin Immunol. 2008 Feb;121(2):486-91. Epub 2007 Nov 26.

PMID: 18036648 [PubMed - indexed for MEDLINE]

20:

CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.

Becker Y.

Virus Genes. 2005 Mar;30(2):251-66. Review.

PMID: 15744581 [PubMed - indexed for MEDLINE]

Recent Activity